Novartis gets FDA warning about Austrian plant
This article was originally published in Scrip
Novartis's Sandoz unit needs to get its Austrian Unterach plant in order after a US FDA warning letter detailed a number of violations, including the manufacturing and distribution of "unapprovable" finished drugs in the US.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.